NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Seasonal InfluenzaInfluenzaInfluenza Due to Unspecified Influenza VirusHuman Influenza

Interventions

BIOLOGICAL

MF59C.1-adjuvanted subunit influenza vaccine

2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm

BIOLOGICAL

Sub unit, Inactivated, Influenza vaccine

2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm

Trial Locations (2)

Site 21: GZA campus Sint Vincentius, Antwerp

Site 22: Kinderartsenpraktijk, Hasselt